AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

12,054.00p
   
  • Change Today:
    290.00p
  • 52 Week High: 15,316.00
  • 52 Week Low: 11,460.00
  • Currency: UK Pounds
  • Shares Issued: 1,551.05m
  • Volume: 88,324
  • Market Cap: £186,964m
  • RiskGrade: 123
  • Beta: 0.00

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

AstraZeneca Financials

Latest F'cast
Div Yield 1.9% 0.0%
Div Cover 2.1 3.1
Op Mrgn 23.4% 31.6%
ROCE 59.5%  
Latest F'cast
P/E 26.0 20.4
PEG 0.6 n/a
Pr/Revenue 4.5 3.8
Pr/Book 5.5  
Latest F'cast
Revenue 8.6% -18.6%
PBT 42.7% 21.8%
EPS 45.4% 54.5%
DPS 3.2% -40.3%

AstraZeneca Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-21 37,417.00 (265.00) 8.00¢ 1,434.6 n/a -97% 287.00¢ 2.5%
31-Dec-22 44,351.00 2,501.00 212.00¢ 70.0 0.0 +2,550% 290.00¢ 2.0%
31-Dec-23 45,811.00 6,899.00 726.00¢ 19.3 0.1 +242% 290.00¢ 2.1%
31-Dec-24 54,073.00 8,691.00 454.00¢ 30.5 n/a -38% 310.00¢ 2.2%
31-Dec-25 58,739.00 12,402.00 660.00¢ 27.6 0.6 +45% 320.00¢ 1.8%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AstraZeneca Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-26 63,208.02 19,983.64 772.14p 15.2 0.3 +54% 252.85p 0.0%
31-Dec-27 67,000.23 22,113.83 858.86p 13.7 1.2 +11% 267.98p 0.0%

Copyright © 2026 FactSet Research Systems Inc. All rights reserved.

AstraZeneca Company Announcements

Director/PDMR Shareholding 22-Dec-2025 11:00 RNS
Enhertu granted BTD for post-neoadjuvant early BC 22-Dec-2025 07:30 RNS
Update on LATIFY Phase III trial of ceralasertib 22-Dec-2025 07:00 RNS

AstraZeneca ShareCast News

AstraZeneca to invest $2bn in Summit Therapeutics 29-Sep-2026 ShareCast
Astrazeneca's Trixeo Aerosphere secures EU appro... 23-Sep-2026 ShareCast
Astrazeneca secures two positive regulatory opin... 21-Sep-2026 ShareCast

AstraZeneca Top Newspaper Links

AstraZeneca takes $2bn stake in US cancer specia... 29-Sep-2026 Times
Is now the right time to buy shares in AstraZene... 04-Aug-2026 Times
AstraZeneca shares fall on Bristol Myers Squibb ... 03-Aug-2026 Times

Latest AstraZeneca Director Deals

Traded Action Notifier PriceAmountValue
14-Sep-26 Buy Pascal Soriot 12,102.00p 60,000 £7,261,199.80
14-Sep-26 Buy Dividends Aradhana Sarin 0.000p 73 £0.00
14-Sep-26 Buy Michel Demare 12,121.33p 2,500 £303,033.24

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 12,054.00p
Change Today 290.00p
% Change 2.47 %
52 Week High 15,316.00
52 Week Low 11,460.00
Volume 88,324
Shares Issued 1,551.05m
Market Cap £186,964m
Beta 0.00
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
93.04% below the market average93.04% below the market average93.04% below the market average93.04% below the market average93.04% below the market average
89.19% below the sector average89.19% below the sector average89.19% below the sector average89.19% below the sector average89.19% below the sector average
Price Trend
11.86% above the market average11.86% above the market average11.86% above the market average11.86% above the market average11.86% above the market average
48.84% above the sector average48.84% above the sector average48.84% above the sector average48.84% above the sector average48.84% above the sector average
Income
65.02% below the market average65.02% below the market average65.02% below the market average65.02% below the market average65.02% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
86.76% above the market average86.76% above the market average86.76% above the market average86.76% above the market average86.76% above the market average
71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average

What The Brokers Say

Strong Buy 10
Buy 8
Neutral 5
Sell 0
Strong Sell 0
Total 23
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  1st Interim 2nd Interim
Ex-Div 06-Aug-26 19-Feb-26
Paid 08-Sep-26 23-Mar-26
Amount 106.00¢ 217.00¢

Trades for 06-Oct-2026

Time Volume / Share Price
08:10 10 @ 12,054.00p
08:10 7 @ 12,054.00p
08:10 3 @ 12,054.00p
08:10 2 @ 12,054.00p
08:10 6 @ 12,054.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page